WallStreetZenWallStreetZen

NASDAQ: IMRX
Immuneering Corp Earnings & Revenue

Buy IMRX

IMRX past revenue growth

How has IMRX's revenue growth performed historically?
Company
-41.19%
Industry
1,026.85%
Market
157.46%
IMRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
IMRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

IMRX earnings and revenue history

Current Revenue
$1.5M
Current Earnings
-$40.2M
Current Profit Margin
-2,652.8%

IMRX Return on Equity

Current Company
-38%
Current Industry
6.9%
Current Market
38.4%
IMRX's Return on Equity (-38%)... subscribe to Premium to read more.
High Return on Equity Performance

IMRX Return on Assets

Current Company
-30%
Current Industry
5.1%
IMRX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

IMRX Return on Capital Employed

Current Company
-27.23%
Current Industry
-16.5%

IMRX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
IMRX$1.52M-$40.18M-$40.20M-41.19%N/A
FENC$0.00-$16.13M-$16.31M-100.00%N/A
TALS$0.00-$55.82M-$56.79MN/AN/A
VOR$0.00-$72.75M-$77.91MN/AN/A
STSA$0.00-$55.67M-$56.23MN/AN/A

Immuneering Earnings & Revenue FAQ

What were IMRX's earnings last quarter?

Immuneering (NASDAQ: IMRX) reported Q1 2022 earnings per share (EPS) of -$0.49, up 61.11% year over year. Total Immuneering earnings for the quarter were -$12.90 million. In the same quarter last year, Immuneering's earnings per share (EPS) was -$1.26.

If you're new to stock investing, here's how to buy Immuneering stock.

What was IMRX's earnings growth in the past year?

As of Q3 2022, Immuneering's earnings has grown year over year. Immuneering's earnings in the past year totalled -$40.20 million.

What was IMRX's revenue last quarter?

Immuneering (NASDAQ: IMRX) reported Q1 2022 revenue of $183.70 thousand up 75.45% year over year. In the same quarter last year, Immuneering's revenue was $748.20 thousand.

What was IMRX's revenue growth in the past year?

As of Q3 2022, Immuneering's revenue has grown -41.19% year over year. This is 1,068.04 percentage points lower than the US Biotechnology industry revenue growth rate of 1,026.85%. Immuneering's revenue in the past year totalled $1.52 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.